Schedule 13G - Passive Investments
Brian Matthew Bloom and associated entities disclose a 7.35% beneficial ownership stake in Satellos Bioscience Inc.
Qiming U.S. Healthcare Fund III, L.P. and related entities have reported beneficial ownership of 8.3% of Satellos Bioscience Inc. common shares as of March 31, 2026.